Featured Editorial

  1. Intratumoral Treatment Of Cancer: After Many Prior Attempts, Has The Time Finally Come? 10/15/2026

    Several companies are in Phase 3 development of intratumoral drug products, all with a lead product in a cancer other than melanoma, based on novel chemistry.

  2. Crossing The Uncrossable: Skin Biology For The Delivery Of Peptide And Protein Therapeutics 10/14/2026

    The skin excludes water-soluble macromolecules from getting through. Delivery science has answered not by defeating the barrier but by dismantling specific mechanisms. Let's take a closer look.

  3. When The Adhesive Becomes The Drug Delivery System 10/13/2026

    The adhesive is not the component that keeps the patch on the patient. It is the formulation, and the physical state of the drug inside it is a design choice whether or not anyone makes it deliberately. 

  4. Antibody–Oligonucleotide Conjugates, Part 1: Approaching Your AOC Development Plan 10/9/2026

    The emergence of antibody–oligonucleotide conjugates (AOCs) addresses delivery issues with huge potential. Let's look at how to approach your development plan with molecular architecture, defining the target product profile, and CQAs.

  5. Drug–Device Combination Products: Bridging Formulation, Device, And Manufacturing Decisions 10/8/2026

    Teams must assess the drug, the device, the manufacturing process, and the environment in which the product is used as an integrated system, not as separate parts. 

  6. Rethinking Drug Delivery To Combat Antibiotic Resistance 10/7/2026

    Combating antibiotic resistance requires delivering therapeutic agents to the right pathogen, cellular target, and site of infection while limiting unnecessary exposure elsewhere.

  7. The Resurgence Of Fervor For Oral Delivery 10/7/2026

    In this article, Chief Editor Tom von Gunden reports on the science and technology boosting the rise in attention to oral methods for advanced drug and biologics delivery. The insights he illuminates include innovative approaches to increasing permeability, solubility, and bioavailability, as well as expanding the types and sizes of therapeutic payloads formulated for oral administration.

  8. Advancing Multi-Pathology Disease-Modifying Therapy For Neurodegenerative Diseases 10/6/2026

    We discuss Amyl’s approach to developing therapeutics designed to target multiple amyloid fibrils and the use of brain shuttle technology to enhance delivery across the blood-brain barrier.

  9. Container Closure Systems For Biosimilars: Is There Regulatory Difference? 10/6/2026

    In this article, Fran DeGrazio discusses the FDA’s draft guidance on container closure systems for biosimilar products. She highlights key takeaways and offers recommendations on implications that developers of biosimilar pharmaceutical products should consider in areas such as quality, testing, and documentation.

  10. Qualification And Validation Of Depyrogenation Tunnels And Autoclaves 10/2/2026

    Systemic vulnerabilities exist in thermal uniformity assurance, steam penetration verification, regulatory fragmentation, and tech harmonization.